All In Biotech

Drug Trial Radar · NCT02319837

Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)

A PHASE 3, RANDOMIZED, EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE, ENZALUTAMIDE MONOTHERAPY, AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGH-RISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,068 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,068

Actual

Start

Dec 17, 2014

Primary completion

Jan 31, 2023

Study completion Jul 30, 2027

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
Collaborators
Astellas Pharma Inc; Medivation LLC, a wholly owned subsidiary of Pfizer Inc.
First posted
Dec 18, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Primary purpose
Treatment
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess enzalutamide plus leuprolide in patients with high-risk nonmetastatic prostate cancer progressing after radical prostatectomy or radiotherapy or both. The randomized / blinded portion of the study is now completed following primary endpoint analyses. The study remains ongoing in open label format.

Conditions

  • Hormone Sensitive Prostate Cancer
  • Prostate Cancer
  • Cancer of the Prostate

Interventions

  • EnzalutamideDrug

  • Placebo (No longer applicable in Open Label study period)Drug

    Sugar pill to mimic enzalutamide

  • Leuprolide Open LabelDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Metastasis-free Survival (MFS) Compared Between Enzalutamide Plus Leuprolide and Placebo Plus LeuprolideTime frame: From randomization until radiographic progression or death without radiographic progression, whichever occurred first (up to Month 98 when at least 197 MFS events occurred among the 3 treatment groups)

Locations

255 sites in 17 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • University of Alabama at Birmingham, IDS Pharmacy

    Birmingham, Alabama

  • Alaska Urological Institute dba Alaska Clinical Research Center

    Anchorage, Alaska

  • Arizona Urology Specialists

    Tucson, Arizona

  • Tower Hematology Oncology Medical Group

    Beverly Hills, California

  • Cedars-Senai OCC Pharmacy

    Los Angeles, California

  • Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute

    Los Angeles, California

  • University of California, Irvine Medical Center

    Orange, California

  • Sutter Medical Group, Vascular & Varicose Vein Center

    Roseville, California

  • Sutter Medical Group

    Roseville, California

  • UC Davis Comprehensive Cancer Center

    Sacramento, California

  • University of California Davis Medical Center

    Sacramento, California

  • University of California, Davis, School of Medicine

    Sacramento, California

  • The Urology Center of Colorado

    Denver, Colorado

  • Foothills Urology, P.C.

    Golden, Colorado

  • Eastern Connecticut Hematology Oncology Associates

    Norwich, Connecticut

  • Lakeland Regional Health Hollis Cancer Center

    Lakeland, Florida

  • Emory University Hospital

    Atlanta, Georgia

  • Winship Cancer Institute, Emory University

    Atlanta, Georgia

  • Emory University Hospital

    Atlanta, Georgia

  • Northwestern Medical Group

    Chicago, Illinois

  • Northwestern Memorial Hospital

    Chicago, Illinois

  • First Urology, PSC

    Jeffersonville, Indiana

  • The University of Kansas Hospital

    Kansas City, Kansas

  • Kansas City Urology Care, PA

    Overland Park, Kansas

  • The University of Kansas Cancer Center and Medical Pavilion

    Westwood, Kansas

  • GU Research Network/Wichita Urology Group

    Wichita, Kansas

  • John Hopkins University Hospital

    Baltimore, Maryland

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    Baltimore, Maryland

  • The Sidney Kimmel Cancer Center at Johns Hopkins Hospital- Oncology Investigational Drug Services

    Baltimore, Maryland

  • Chesapeake Urology Research Associates

    Towson, Maryland

  • Comprehensive Urology - Macomb Office

    Macomb, Michigan

  • Comprehensive Urology - Royal Oak (Stephenson) office

    Royal Oak, Michigan

  • GU Research Network, LLC / Urology Cancer Center

    Omaha, Nebraska

  • VA Lahontan Valley Outpatient Clinic

    Fallon, Nevada

  • Memorial Sloan Kettering Cancer Center Basking Ridge

    Basking Ridge, New Jersey

  • Memorial Sloan Kettering Cancer Center Commack

    Commack, New York

  • Memorial Sloan Kettering Cancer Center Westchester

    Harrison, New York

  • Memorial Hospital

    New York, New York

Showing 40 of 255 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.